Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Zhongyuan Union Cell & Gene Engineering had a gross margin of 69.57% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Zhongyuan Union Cell & Gene Engineering Gross Margin % Related Terms
Zhongyuan Union Cell & Gene Engineering Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering Gross Margin % Chart
Zhongyuan Union Cell & Gene Engineering Annual Data
SHSE:600645 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongyuan Union Cell & Gene Engineering Gross Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a Gross Margin % of 69.57% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. This is near median its historical median of 67.65. Over the past decade, Zhongyuan Union Cell & Gene Engineering's Gross Margin % has ranged from 64.80 to 70.16. According to the industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #294 out of 732 companies in the Biotechnology industry, placing it in the top 40.2%.
Is Zhongyuan Union Cell & Gene Engineering's Gross Margin % too high?
Zhongyuan Union Cell & Gene Engineering's current Gross Margin % of 69.57% is near median its 10-year median of 67.65. Over the past 10 years, this metric has ranged from a low of 64.80 to a high of 70.16. The Biotechnology industry median Gross Margin % is 60.91. Zhongyuan Union Cell & Gene Engineering's value of 69.57% is 14.2% above this industry median. Based on the distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #294 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #294 out of 732 companies for Gross Margin %. This puts Zhongyuan Union Cell & Gene Engineering in the upper half of its industry. The industry median Gross Margin % is 60.91. Zhongyuan Union Cell & Gene Engineering's value of 69.57% is 14.2% above this benchmark. Historically, Zhongyuan Union Cell & Gene Engineering's own Gross Margin % has ranged from 64.80 to 70.16 over the past decade. While the company's 10-year median is 67.65 vs. the industry median of 60.91, Zhongyuan Union Cell & Gene Engineering has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhongyuan Union Cell & Gene Engineering's current Gross Margin % of 69.57% is 14.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhongyuan Union Cell & Gene Engineering's current Gross Margin % is 69.57%, which is near median its own 10-year median of 67.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥20.36, compared to a current price of ¥18.09 — trading 11.1% below its estimated fair value. The current Gross Margin % is 69.57%, which is near median its 10-year median of 67.65 and 14.2% above the Biotechnology industry median of 60.91. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current Gross Margin % is 69.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be undervalued.
The current stock price of ¥18.09 is trading 11.1% below its estimated GF Value™ of ¥20.36.
GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:600645:
Gross Margin %: 69.57% (near median its 10-year median of 67.65)
GF Value™: ¥20.36 vs. price of ¥18.09 (11.1% below fair value)
Industry Position: 14.2% above the Biotechnology median (#294 of 732)
No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongyuan Union Cell & Gene Engineering Business Description
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
60GF Score
Get the complete analysis for SHSE:600645
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600645 has been successfully added to your 
